Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion. [electronic resource]
Producer: 20090625Description: 1325-37 p. digitalISSN:- 1539-2864
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Female
- Follow-Up Studies
- Humans
- Injections
- Macula Lutea -- drug effects
- Macular Edema -- diagnosis
- Male
- Middle Aged
- Retinal Vein Occlusion -- complications
- Retrospective Studies
- Time Factors
- Tomography, Optical Coherence
- Treatment Outcome
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
- Visual Acuity -- drug effects
- Vitreous Body
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.